LLYCL
Eli Lilly and Company · BCS:LLYCL
1,290,000.00 CLP150,000.00 +13.16%
Eli Lilly and Company (BCS:LLYCL) last traded at 1,290,000.00 CLP, up 13.16% on the day. Over the past year the stock is up 65.87%. Its 52-week range is 766,500.00 to 1,290,000.00. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open1,290,000.00
Day range1,290,000.00 – 1,290,000.00
52-week range766,500.00 – 1,290,000.00
Volume2
Average volume (10 days)7
Market cap (USD)1.33 T
P/E43.40
EPS (TTM) (USD)30.44
Dividend yield0.47%
Beta (1 year)−0.1703
Revenue (TTM) (USD)86.46 B
Employees50.00 K
Performance
+13.36%1 week
+24.65%1 month
+22.27%3 months
+52.10%6 months
+31.87%Year to date
+65.87%1 year
Technical rating
Strong buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
1,447,711.43 CLP
The average 1-year price target, +12.23% from the last price. See the forecast
Latest headlines
- Notable healthcare headlines for the week: Eli Lilly, Merck, and AstraZeneca in focusSeeking Alpha · 01 Nov 2026
- Healthcare sector rallies in October amid rotation away from technology stocksSeeking Alpha · 31 Oct 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech SkepticismBenzinga · 31 Oct 2026
- Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3Stocktwits · 31 Oct 2026
- Eli Lilly Is Maintained at Buy by UBSDow Jones Newswires · 31 Oct 2026
- UBS maintains Eli Lilly at Buy, raises price target to $1625 from $1425TradingView · 31 Oct 2026
- What Eli Lilly and Company (LLY) Said on Its Q3 Earnings CallMarketBeat · 30 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.